secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001193125-24-219153
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports promising Phase 1 data for zidesamtinib and NVL-655; pivotal data expected 2025
--------------------------------------------------------------------------------

- Zidesamtinib ORR 44% in pre-treated ROS1+ NSCLC; 72% in G2032R mutation subset.
- NVL-655 at RP2D showed ORR 38% in pre-treated ALK+ NSCLC; 64% in compound mutation patients.
- Phase 2 enrollment accelerated: 227 patients in ARROS-1, 229 in ALKOVE-1 as of Sept 1, 2024.
- Phase 3 ALKAZAR trial of NVL-655 vs alectinib in TKI-naïve ALK+ NSCLC to start H1 2025; FDA aligned.
- Pivotal data from both Phase 2 trials now expected in 2025; no discontinuations due to TRAEs for zidesamtinib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000119312524219153/0001193125-24-219153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000119312524219153/d862522d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-219153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer